Chatham Capital Group Inc. Has $7.51 Million Holdings in Johnson & Johnson (JNJ)

Parametric Portfolio Associates LLC now owns 7,970,670 shares of the company's stock worth $1,054,433,000 after acquiring an additional 2,581,562 shares during the period. The hedge fund run by Ray Carroll held 253,279 shares of the real estate investment trusts company at the end of 2017Q3, valued at $10.40 million, up from 234,244 at the end of the previous reported quarter. Capital Investment Counsel Inc who had been investing in Cisco Sys Inc for a number of months, seems to be bullish on the $218.57B market cap company. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 0.66% with $2.69 Billion sitting short, betting on future declines. 7,560,000 shares of the stock traded hands, compared to its average volume of 8,770,000. It has underperformed by 4.16% the S&P500.

Chatham Capital Group Inc. grew its stake in Johnson & Johnson (NYSE:JNJ) by 0.9% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. Northeast Financial Consultants Inc bought 3,388 shares as the company's stock rose 6.85% with the market. The institutional investor held 46,088 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $3.90 million, down from 71,844 at the end of the previous reported quarter. Breton Hill Capital Ltd who had been investing in Liberty Ppty Tr for a number of months, seems to be bullish on the $6.14B market cap company. It opened the session with a $129.46 price tag, later ranging from $129.33 to $132.3, the range at which the stock has traded at throughout the day.

Johnson & Johnson (JNJ) closed the Wednesday at final price of $129.04 after traded 6389904 shares.

Johnson & Johnson (NYSE:JNJ) said Thursday the average price paid for its medicines in the USA fell by 4.6% last year due to the company's discounts, and the company's pharmaceuticals chief expects the pricing pressures on drugmakers will continue this year. It has underperformed by 12.66% the S&P500. Johnson & Johnson now has a consensus rating of "Hold" and an average price target of $146.26. Therefore 40% are positive. On Wednesday, February 21 the stock rating was maintained by Leerink Swann with "Market Perform".

Among 15 analysts covering Canadian Imperial Bank Of Commerce (NYSE:CM), 6 have Buy rating, 2 Sell and 7 Hold.

NetEase, Inc. (NTES) opened the session with a $308.9 price tag, later ranging from $307.15 to $314.19, the range at which the stock has traded at throughout the day. The firm has "Overweight" rating given on Thursday, January 21 by Barclays Capital. The firm has "Mkt Perform" rating given on Friday, February 24 by Keefe Bruyette & Woods. On Monday, February 26 the insider BURNS M MICHELE sold $550,153. (NASDAQ:HSIC) rating on Thursday, July 20. The firm has "Outperform" rating by Macquarie Research given on Monday, July 27. The firm has "Hold" rating by Jefferies given on Tuesday, November 7. The rating was maintained by Oppenheimer with "Hold" on Tuesday, August 29.

More news: Kawhi Leonard could return as early as Thursday

Investors sentiment increased to 1.12 in 2017 Q3. Its up 5.99, from 1.16 in 2017Q2. Aspen Invest Mgmt Inc has 7,152 shares for 0.41% of their portfolio.

Glynn Capital Management Llc holds 4.6% of its portfolio in Veeva Systems Inc. for 324,692 shares. Hilltop holds 17,181 shares. 13,044 were reported by Wellington Management Gp Llp. (NASDAQ:SGEN). Franklin Resource Inc has invested 0% in Seattle Genetics, Inc. Sg Americas Ltd has invested 0.09% in Medtronic plc (NYSE:MDT). (NASDAQ:SGEN) or 52,033 shares. Us Bank De reported 0.03% stake. Nepsis Management Inc holds 3.3% or 49,203 shares. Sivik Limited Liability holds 30,000 shares. Sabal holds 233,336 shares.

Investors sentiment is 0.83 in Q3 2017. Its the same as in 2017Q2. It also reduced its holding in News Corp New (NASDAQ:NWS) by 166,900 shares in the quarter, leaving it with 1.58M shares, and cut its stake in Expeditors Intl Wash Inc (NASDAQ:EXPD). Wedgewood Incorporated Pa holds 11,977 shares or 1.31% of its portfolio.

Several other large investors have also bought and sold shares of JNJ. Needelman Asset Mgmt stated it has 9,795 shares or 3.13% of all its holdings. Burt Wealth Advisors holds 12,158 shares. Johnson & Johnson makes up 1.5% of Mawer Investment Management Ltd.'s holdings, making the stock its 25th biggest position. 5,090 were reported by Provident. State Treasurer State Of Michigan owns 1.06% invested in Johnson & Johnson (NYSE:JNJ) for 1.01 million shares. Martin Investment Management Limited Liability owns 85,217 shares. Boys Arnold And Incorporated holds 1.76% or 85,160 shares in its portfolio. Cohen & Steers reported 65,668 shares. Somerset Gru Ltd Liability reported 0.29% in Johnson & Johnson (NYSE:JNJ). Griffin Asset Mngmt has invested 0.05% of its portfolio in Seattle Genetics, Inc. Private Tru Com Na stated it has 50,258 shares.

Since January 1, 0001, it had 0 insider buys, and 25 selling transactions for $17.37 million activity. Four equities research analysts have rated the stock with a sell rating, nine have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Therefore 27% are positive. Seattle Genetics had 64 analyst reports since July 31, 2015 according to SRatingsIntel. Argus Research has "Buy" rating and $130 target. Finally, Royal Bank of Canada reiterated a "buy" rating on shares of Johnson & Johnson in a research note on Tuesday, January 9th. CLSA downgraded the stock to "Outperform" rating in Monday, May 9 report. Vetr upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating and set a $152.28 price target for the company in a report on Monday, February 5th. The company was maintained on Friday, January 12 by Wells Fargo. The stock of Johnson & Johnson (NYSE:JNJ) has "Hold" rating given on Wednesday, January 24 by Stifel Nicolaus. The stock has "Buy" rating by UBS on Tuesday, September 22. The company's revenue for the quarter was up 11.5% on a year-over-year basis. research analysts anticipate that Johnson & Johnson will post 8.11 earnings per share for the current year. The rating was maintained by Needham with "Buy" on Wednesday, August 23.

Latest News